TY - JOUR
T1 - Increased alternative complement pathway function and improved Survival during Critical Illness
AU - Bain, William
AU - Li, Huihua
AU - van der Geest, Rick
AU - Moore, Sara R.
AU - Olonisakin, Tolani F.
AU - Ahn, Brian
AU - Papke, Erin
AU - Moghbeli, Kaveh
AU - DeSensi, Rebecca
AU - Rapport, Sarah
AU - Saul, Melissa
AU - Hulver, Mei
AU - Xiong, Zeyu
AU - Mallampalli, Rama K.
AU - Ray, Prabir
AU - Morris, Alison
AU - Ma, Lina
AU - Doi, Yohei
AU - Zhang, Yingze
AU - Kitsios, Georgios D.
AU - Kulkarni, Hrishikesh S.
AU - McVerry, Bryan J.
AU - Ferreira, Viviana P.
AU - Nouraie, Mehdi
AU - Lee, Janet S.
N1 - Funding Information:
Supported by the NHLBI of the NIH under award numbers 4T32 HL007563, F32 HL142172, and L30 HL143734 (W.B.); K23 HL129987 (G.D.K); K08 HL148510 (H.S.K.); P01HL114453 (R.K.M., P.R., B.J.M., and J.S.L.); R01 HL097376 (B.J.M.); K24 HL123342 (A.M.); R01HL112937 (V.P.F.); R01 HL136143, R01 HL142084, and K24 HL143285 (J.S.L.); Career Development award number IK2 BX004886 from the U.S. Department of Veterans Affairs Biomedical Laboratory R&D (BLRD) Service (W.B.); American Heart Association Pre-Doctoral Fellowship 18PRE33960033 (T.F.O.); Lung Association and Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital (PD-FR-2020–867) (H.S.K.); and the Vascular Medicine Institute, the Hemophilia Center of Western Pennsylvania, and the Institute for Transfusion Medicine (W.B). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, Department of Veterans Affairs, or any other sponsoring agency.
Publisher Copyright:
© 2020 by the American Thoracic Society.
PY - 2020/7/15
Y1 - 2020/7/15
N2 - Rationale: Complement is crucial for host defense butmay also drive dysregulated inflammation. There is limited understanding of alternative complement function, which can amplify all complement activity, during critical illness. Objectives: We examined the function and key components of the alternative complement pathway in a series of critically ill patients and in a mouse pneumonia model. Methods: Total classical (CH50) and alternative complement (AH50) function were quantified in serum from 321 prospectively enrolled critically ill patients and compared with clinical outcomes. Alternative pathway (AP) regulatory factors were quantified by ELISA (n = 181) and examined via transcriptomics data from external cohorts. Wild-type, Cfb2/2, and C32/2 mice were infected intratracheally with Klebsiella pneumoniae (KP) and assessed for extrapulmonary dissemination. Measurements and Main Results: AH50 greater than or equal to median, but not CH50 greater than or equal to median, was associated with decreased 30-day mortality (adjusted odds ratio [OR], 0.53 [95% confidence interval (CI), 0.31 0.91]), independent of chronic liver disease. One-year survival was improved in patients with AH50 greater than or equal to median (adjusted hazard ratio = 0.59 [95% CI, 0.41 0.87]). Patients with elevated AH50 had increased levels of AP factors B, H, and properdin, and fewer showed a hyperinflammatory subphenotype (OR, 0.30 [95% CI, 0.18 0.49]). Increased expression of proximal AP genes was associated with improved survival in two external cohorts. AH50 greater than or equal to median was associated with fewer bloodstream infections (OR, 0.67 [95% CI, 0.45 0.98). Conversely, depletion of AP factors, or AH50 less than median, impaired in vitro serum control of KP that was restored by adding healthy serum. Cfb2/2 mice demonstrated increased extrapulmonary dissemination and serum inflammatory markers after intratracheal KP infection compared with wild type. Conclusions: Elevated AP function is associated with improved survival during critical illness, possibly because of enhanced immune capacity.
AB - Rationale: Complement is crucial for host defense butmay also drive dysregulated inflammation. There is limited understanding of alternative complement function, which can amplify all complement activity, during critical illness. Objectives: We examined the function and key components of the alternative complement pathway in a series of critically ill patients and in a mouse pneumonia model. Methods: Total classical (CH50) and alternative complement (AH50) function were quantified in serum from 321 prospectively enrolled critically ill patients and compared with clinical outcomes. Alternative pathway (AP) regulatory factors were quantified by ELISA (n = 181) and examined via transcriptomics data from external cohorts. Wild-type, Cfb2/2, and C32/2 mice were infected intratracheally with Klebsiella pneumoniae (KP) and assessed for extrapulmonary dissemination. Measurements and Main Results: AH50 greater than or equal to median, but not CH50 greater than or equal to median, was associated with decreased 30-day mortality (adjusted odds ratio [OR], 0.53 [95% confidence interval (CI), 0.31 0.91]), independent of chronic liver disease. One-year survival was improved in patients with AH50 greater than or equal to median (adjusted hazard ratio = 0.59 [95% CI, 0.41 0.87]). Patients with elevated AH50 had increased levels of AP factors B, H, and properdin, and fewer showed a hyperinflammatory subphenotype (OR, 0.30 [95% CI, 0.18 0.49]). Increased expression of proximal AP genes was associated with improved survival in two external cohorts. AH50 greater than or equal to median was associated with fewer bloodstream infections (OR, 0.67 [95% CI, 0.45 0.98). Conversely, depletion of AP factors, or AH50 less than median, impaired in vitro serum control of KP that was restored by adding healthy serum. Cfb2/2 mice demonstrated increased extrapulmonary dissemination and serum inflammatory markers after intratracheal KP infection compared with wild type. Conclusions: Elevated AP function is associated with improved survival during critical illness, possibly because of enhanced immune capacity.
KW - Complement
KW - Critical illness
KW - Host defense
KW - Pneumonia
KW - Serum
UR - http://www.scopus.com/inward/record.url?scp=85088178220&partnerID=8YFLogxK
U2 - 10.1164/rccm.201910-2083OC
DO - 10.1164/rccm.201910-2083OC
M3 - Article
C2 - 32374177
AN - SCOPUS:85088178220
SN - 1073-449X
VL - 202
SP - 230
EP - 240
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 2
ER -